Candel Therapeutics (CADL) Interest & Investment Income (2020 - 2025)
Candel Therapeutics' (CADL) quarterly Interest & Investment Income came in at $1.1 million in Q4 2025, up 280.0% year-on-year from $290000.0 in Q4 2024, and up 15.63% quarter-over-quarter from $953000.0 in Q3 2025.
Candel Therapeutics (CADL) Interest & Investment Income (2020 - 2025) Analysis & Trends
Candel Therapeutics has disclosed Interest & Investment Income across 6 years of filings, most recently posting $1.1 million for Q4 2025.
- Interest & Investment Income for Q4 2025 came in at $1.1 million, up 280.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $3.9 million (up 260.5% YoY), and the FY2025 annual result was $3.9 million, up 260.5% from the prior year.
- Interest & Investment Income came in at $1.1 million for Q4 2025 at Candel Therapeutics, up from $953000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $1.1 million in Q4 2025 to a low of -$175000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $331500.0 (2022), against an average of $403600.0.
- Peak annual rise in Interest & Investment Income reached 7409.09% in 2022, while the deepest fall reached 1358.33% in 2022.
- Candel Therapeutics' Interest & Investment Income stood at -$11000.0 in 2021, then surged by 7409.09% to $804000.0 in 2022, then plunged by 48.38% to $415000.0 in 2023, then tumbled by 30.12% to $290000.0 in 2024, then soared by 280.0% to $1.1 million in 2025.
- The last three Interest & Investment Income figures came in at $1.1 million (Q4 2025), $953000.0 (Q3 2025), and $926000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 597,319.59 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -14.79 Mn |
| 10 | Candel Therapeutics | 453.59 Mn | 453.59 Mn | - | 1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 953,000.00 |
| Jun 30, 2025 | 926,000.00 |
| Mar 31, 2025 | 934,000.00 |
| Dec 31, 2024 | 290,000.00 |
| Sep 30, 2024 | 236,000.00 |
| Jun 30, 2024 | 240,000.00 |
| Mar 31, 2024 | 320,000.00 |
| Dec 31, 2023 | 415,000.00 |
| Sep 30, 2023 | 502,000.00 |
| Jun 30, 2023 | 453,000.00 |
| Mar 31, 2023 | 711,000.00 |
| Dec 31, 2022 | 804,000.00 |
| Sep 30, 2022 | 343,000.00 |
| Jun 30, 2022 | 70,000.00 |
| Mar 31, 2022 | -175,000.00 |
| Dec 31, 2021 | -11,000.00 |
| Sep 30, 2021 | -14,000.00 |
| Jun 30, 2021 | -15,000.00 |
| Mar 31, 2021 | -12,000.00 |